Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14761200 | 0.93 | CYP2D6 (0.74) | CYP2D6TSHRPOLBMEN1KMT2A | |
| SCHEMBL14761718 | 0.91 | DRD3 (0.71) | CYP2D6TSHRPOLBMEN1KMT2A | |
| SCHEMBL12916046 | 0.81 | SIGMAR1 (0.64) | KMT2ASIGMAR1 | |
| SCHEMBL19554726 | 0.80 | KDM4E (0.72) | TSHRALDH1A1CHRM4 | |
| SCHEMBL2262431 | 0.79 | CHRM4 (0.65) | CYP2D6TSHRPOLBMEN1KMT2A | |
| SCHEMBL6378224 | 0.79 | CYP2C19 (0.70) | KMT2ASIGMAR1DRD2DRD3 | |
| SCHEMBL19849339 | 0.79 | ALOX15 (0.59) | TSHRMEN1KMT2AALDH1A1DRD2 | |
| SCHEMBL17468810 | 0.78 | SIGMAR1 (0.61) | CYP2D6TSHRPOLBMEN1KMT2A | |
| SCHEMBL8185713 | 0.78 | CYP2C19 (0.62) | CYP2D6KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL24075739 | 0.78 | SLC6A2 (0.70) | CYP2D6MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | CYP2D6 572/4885TSHR 443/4885POLB 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.